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KCC2 is the main Cl -extruder of neurons, so it is crucial for the maintenance of low [Cl - ] i levels in neurons. Thus, the proper inhibitory function of GABA is maintained by the proper activity of KCC2 (for review: Ben-Ari, 2002; Owens and Kriegstein, 2002; Fukuda, 2013; Kaila et al., 2014) .
Epilepsy, which is caused primarily by an imbalance of excitation and inhibition, may be the most relevant disease for SLC12A5 variants. Indeed, excitatory GABA responses accompanied by decreases in KCC2 expression and increases in [Cl - ] i have been reported in human epileptic tissue (Cohen et al., 2002; D'Antuono et al., 2004; Huberfeld et al., 2007) .
Although elucidation of SLC12A5 variants causal for human diseases was difficult for a long time, recent whole exome sequencing has revealed causal SLC12A5 variants in patients with intractable epilepsy (Saitsu et al., 2016; Stödberg et al., 2015) .
Because depolarizing GABA action resulting from upregulation of the Cl -importer Na + ,K + -2Cl -cotransporter 1 (NKCC1), and downregulation of KCC2, is considered to be involved in a variety of cortical developmental processes, such as neurogenesis, migration, and synaptogenesis (Ben-Ari, 2002; Owens and Kriegstein, 2002; Wang and Kriegstein, 2009; Luhmann et al., 2015) , altered Cl -homeostasis may be responsible for the pathogenesis of neurodevelopmental disorders. Common neurodevelopmental disorders including intellectual disability, autism spectrum disorder (ASD), schizophrenia, and epilepsy (Guilmatre et al., 2009; Bozzi et al., 2012) , although classified into distinct disease categories,
show phenotypic overlap and shared genetic risk factors (Mitchell, 2011; Coe et al., 2012) .
Numerous studies have reported impaired GABAergic inhibition as a common feature among different neurodevelopmental disorders (Hashimoto et al., 2008; Kang and Macdonald, 2009; Schmidt and Mirnics, 2014) . Further, neuronal hyperexcitability has been implicated in the pathogenesis of neurodevelopmental disorders, including ASD (Coghlan et al., 2012) and schizophrenia (Lewis et al., 2012) . Therefore, dysfunction of KCC2 is clearly a candidate for the pathogenesis of neurodevelopmental disorders, and consequently, pathogenic SLC12A5 variants in neurodevelopmental disorder patients have also been studied (Kahle et al., 2014; Merner et al., 2015) .
Molecular structure and regulation of KCC2
SLC12A5, in chromosome 20q13.12, encoding the mammalian KCC2, has 26 exons and generates two neuron-specific isoforms, KCC2a and KCC2b, by using alternative promoters and first exons (Uvarov et al., 2007) . The KCC2a isoform differs from KCC2b by 40 unique N-terminal amino acid residues but has comparable ion transport activity with that of KCC2b. KCC2b shows a marked increase in expression during postnatal development. In contrast, KCC2a, which is essential for modulation of neonatal respiratory neural networks (Dubois et al., 2018) , remains relatively constant, and then decreases to contribute only a part of the total KCC2 in the mature brain. In this review, KCC2 denotes KCC2b, unless otherwise mentioned.
[Place Fig. 1 near here]
Based on hydropathy analysis of the KCC2 protein, a model of KCC2, including 12 transmembrane domains flanked by intracellular N-and C-termini was proposed (Payne et al., 1996 ; Fig. 1 ). Although numerous studies suggest an important role of the C-terminus in control of KCC2 activity (see Moore et al., 2017 for review), due to a lack of X-ray crystal structural analysis, its three-dimentional structure and functional aspects remain poorly understood. Recently, Agez et al. (2017) reported molecular structure-function relationships by using purified KCC2 protein and electron microscopy. Purified KCC2 exhibits various posttranslational modification sites, such as six asparagine (N)-linked glycosylation sites (N283, N291, N310, N328, N338 and N339) and serine (S) and threonine (T) phosphorylation sites (S25, S26, S940, T1007 and S1022) (Fig. 1A) . The large carboxy-terminal domain of KCC2 is the target of several known kinases. S940 is well characterized as the phosphorylation site regulated by protein kinase C (PKC) (Lee et al., 2007) . The phosphorylation of this site decreases KCC2 internalization, stabilizing it at the cell surface and then enhancing extrusion of Cl -. Two additional sites near S940, T934 and S937, also upregulate KCC2 transport activity when phosphorylated (Weber et al., 2014) . By contrast, phosphorylation of tyrosine (Y) 903 and Y1087, possibly by Src-family tyrosine kinases (SFK), reduces the membrane stability of KCC2 (Lee et al., 2010) . Conversely, phosphorylation of T906 and T1007 inhibit transport function of KCC2 (Friedel et al., 2015; Inoue et al. 2012; Titz et al., 2015; de Los Heros et al., 2014) . The kinases responsible for the phosphorylation of T1007 are considered to be STE20/SPS1-related proline-alanine-rich protein kinase (SPAK) and the oxidative stress-responsive 1 protein kinase (OSR1) (Fig. 1A ) (de Los Heros et al., 2014; Zhang et al., 2016) , but the kinase for T906 remains unknown.
Interestingly, phosphorylation of T212 on NKCC1 by SPAK or OSR1 activates its function (de Los Heros et al., 2014 and OSR1 at S325, leading to the activation of these kinases (Vitari et al., 2005) . The phosphorylation and function of SPAK/OSR1 may change over development, possibly due to a change in WNK1 activity (Inoue et al., 2012) . Thus, if high phosphorylation of T906/T1007 in KCC2 occurs in immature brains and decreases during development by developmental dephosphorylation of these sites, it may underlie the functional development of the KCC2
protein (Friedel et al., 2015; Rinehart et al., 2009 ) and subsequent hyperpolarizing and inhibitory actions of GABA over development (Friedel et al., 2015; Fukuda, 2013 kinase pathway exist, such as osmotic stress, intracellular and extracellular ions, and nitric oxide (Shekarabi et al., 2017; Murthy et al., 2017; Kim et al., 2018) . Of these, the positive modulator taurine may be most relevant to developmental modulation of the WNK1-SPAK/OSR1 kinase pathway, because taurine is very abundant in the immature brain and then decreases with development (Inoue et al., 2012, Kilb and Fukuda 2017) . This developmental change in taurine is compatible with functional development of KCC2 activity.
In addition to taurine, estradiol (Nugent et al., 2012) KCC2 is also known to form oligomers in an age-dependent manner, as immature brains are characterized by a higher content of monomers, whereas adult tissue produces mostly oligomeric forms of KCC2 (Blaesse et al., 2006) . In terms of molecular assembly, disulfide bridges are involved in KCC2 dimerization and the conserved KCC2 C-terminus may be at the interface of dimerization (Agez et al., 2017) . However, controversy surrounds Medina et al.'s (2014) claim about the use of monomer/dimer ratios as a biochemical measure of KCC2 functional activity. Future experiments will be required to reveal more about the validity of the KCC2 monomer/dimer issue.
Although the degradation pathway of KCC2 is not yet well understood, KCC2 is cleaved at its C-terminal domain by calpain, the Ca 2+ -activated protease, leading to loss of a ~20-40 kDa fragment (Puskarjov et al., 2012) . Because the calpain-removed part of the C-terminal domain contains many of the sites that are critical for the function and regulation of KCC2 (see Fig. 1 ), calpain-mediated cleavage of KCC2 compromises neuronal Cl -extrusion capacity, as mentioned above. However, because the calpain cleavage site is not yet entirely clear, future investigations are needed to reveal more about this regulatory process.
SLC12A5 variants in human diseases

Febrile seizures
Recently, heterozygous missense mutations in SLC12A5 were shown to be associated with febrile seizures (Puskarjov et al., 2014) . Screening of SLC12A5 revealed a co-segregating variant c.2855G>A (p.R952H) in an Australian family with febrile seizures.
KCC2-R952H reduces neuronal Cl -extrusion along with a reduced surface expression, which might contribute to the functional deficits. Additionally, its ability to induce dendritic spines, which is another known function of KCC2 other than Cl -extrusion (Li et al., 2007) , is compromised both in vivo and in vitro. The results suggest that KCC2-R952H is an unquestionable susceptibility variant for febrile seizures (Fig. 1B) .
Idiopathic generalized epilepsy
By a targeted DNA-sequencing approach to screen the C-terminus of KCC2 along with the homologous region in KCC3 (SLC12A6) and the N-terminal regulatory region in NKCC1 (SLC12A2), another independent study also identified the same missense variant, i.e., lowering the intrinsic activity of transporters (R1049C), the results are consistent with the known trafficking-dependent and -independent mechanisms of KCC2 regulation mediated by its C-terminus (Medina et al., 2014) . By changing the C-terminal protein structure, these variants might alter the function of the key regulatory ISO domain (amino acids 1022-1037, see Fig. 1A ), which is required for isotonic KCC2 action (Acton et al., 2012) . Interestingly, both KCC2 R952H and R1049C exhibited a significant >50% decrease in S940 phosphorylation compared with wildtype KCC2, despite comparable levels of total protein expression (Kahle et al., 2014) . These results suggest impaired function of these KCC2
variants is mediated in part by a decrease in S940 phosphorylation (Lee et al., 2007) .
However, these variants (i.e., R952H and R1049C) were identified based only on the targeted DNA sequencing of SLC12A5, and possible causative mutations in other genes were not clearly excluded. Indeed, KCC2 R952H and R1049C can be present in control individuals in cohorts or in patients who inherited them from unaffected parents (Kahle et al., 2014; Puskarjov et al., 2014) , indicating these variants could be risk factors for the development of human febrile seizures and IGE.
Epilepsy of infancy with migrating focal seizures
The first monogenic KCC2-related epilepsy was reported through exome sequencing of two unrelated families, which discovered four infantile patients exhibiting migrating focal seizures (epilepsy of infancy with migrating focal seizures; EIMFS) who carried recessive loss-of-function variants in SLC12A5 (Stödberg et al., 2015) . Owing to confusion regarding KCC2a (NM_001134771.1) and KCC2b (NM_020708.4) in this report, the mutated residues reported correspond to L288H, L403P and G528D in human KCC2b (Fig. 1B) . Two patients had compound heterozygous missense mutations, c.1208T>C (p.L403P) and c.1583G>A
(p.G528D), and the other two (one deceased) possessed a homozygous missense mutation c.863T>A (p.L288H). Functional analysis was obtained from cells co-transfected with a plasmid either encoding the wild-type KCC2b isoform or one of the mutants KCC2-L288H, -L403P or -G528D. The authors concluded that the Cl -extrusion function of L403P and G528D mutants was completely lost, whereas the L288H mutant was still partly functional, and that these functional losses were due to reduced surface expression and glycosylation of these mutants (Stödberg et al., 2015) . Unfortunately however, the equilibrium potential for Cl Another independent study also discovered four additional KCC2 variants as a cause of EIMFS (Saitsu et al., 2016 These data clearly demonstrate that partially disrupted neuronal Cl − extrusion, mediated by two types of differentially impaired KCC2 variants in an individual, causes EIMFS (Fig. 1B ).
More recently, by gene panel sequencing of a patient with EIMFS from a nonconsanguineous family, a compound heterozygous constellation of variants in SLC12A5
was also found (Saito et al., 2017) . Again, owing to confusion of KCC2a and KCC2b in this report, the reported variants corresponded to maternally inherited c.1127C>T (p.S376L) and a de novo c.2570G>T (p.R857L) in human KCC2b (Fig. 1B) .
Although the exact functional role of glycosylation of KCC2 has not yet been determined, three loci of variants (e.g., L288H, W318S, S323P) near the specific glycosylation sites in the extracellular domain (Fig. 1A) imply such glycosylation is required for the trafficking-independent intrinsic function of KCC2. However, the exact functional role of site-specific glycosylation of KCC2 needs to be further investigated.
Neurodevelopmental disorders
The same group who found R952H and R1049C variants in patients with IGE utilized a similar targeted genetic sequencing approach to screen the 3' end of SLC12A5, which encodes the C-terminal regulatory domain of KCC2 (Kahle et al., 2014) ; a total of 427 ASD, 143 schizophrenia and 190 intellectual disability cases were screened (Merner et al., 2015) . The authors reported the two variants previously linked with IGE and familial febrile seizures in human ASD (i.e., R952H and R1049C) and schizophrenia (R952H), and another novel non-synonymous KCC2 variant c.3142C>T (p.R1048W) in ASD, with a highly predicted pathogenicity. This finding suggests that genetically-encoded impairment of KCC2 function may be a risk factor for, or contribute to the pathogenesis of, human ASD and schizophrenia (Fig. 1B) . This paper was the first to describe functional KCC2 genetic variants in human psychiatric diseases, and suggested a compelling genetic overlap between distinct neurodevelopmental disorders. Exome data from 2517 simplex families in the ASD Simon
Simplex Collection revealed significantly more KCC2 C-terminal regulatory domain variants in ASD cases than controls, and interestingly, these were more often synonymous and predicted to disrupt or introduce a CpG site (Merner et al., 2015) . Furthermore, full gene analysis showed ASD cases were more likely to contain rare KCC2 variants affecting CpG sites than controls, suggesting a possible epigenetic effect on gene expression through variation in methylation patterns of DNA. Thus, genetically-encoded dysregulation of KCC2 may also contribute to multiple human neurodevelopmental disorders. Hyde et al. (2011) , reported decreased expression of full-length KCC2 in the postmortem hippocampus of patients with schizophrenia, but not in the dorsolateral prefrontal cortex. SLC12A5, with 26 exons, undergoes alternative splicing, so the same group performed extensive experiments in the dorsolateral prefrontal cortex to identify alternative transcripts of KCC2 to delineate its potential role in brain development and psychiatric disorders (Tao et al., 2012) . They discovered several previously unrecognized alternative KCC2 transcripts in both adult and fetal human brains, in addition to the previously identified full-length and truncated transcripts. The expression levels of four relatively abundant truncated splice variants (ΔEXON6, EXON2B, EXON6B and AK098371), transcripts of which were translated into proteins and expressed at their predicted sizes, were measured in a large human cohort of non-psychiatric controls, and in patients with schizophrenia and affective disorders.
Expression of the EXON6B transcript was increased in the dorsolateral prefrontal cortex of patients with schizophrenia but decreased in patients with major depression. The expression of AK098371 is associated with a GAD1 single nucleotide polymorphism known for a risk for schizophrenia. These data provide evidence that alternative transcripts of KCC2 are differentially expressed in schizophrenia and affective disorders. Thus, alternate transcripts from KCC2 may participate in the abnormal GABA signaling associated with schizophrenia.
Conclusion
KCC2 is one of the most intensively investigated molecules because of its critical roles in development and function of the mature central nervous system. SLC12A5 is among the human genes most intolerant of variation. Therefore, variants in SLC12A5 are likely to contribute to neurological and neurodevelopmental disease phenotypes. Although Cl -extruding abilities of mutant KCC2 (e.g., L288H, L403P, G528D, W318S, S748del, S376L, R857L and R1048W) are yet to be studied, confirmed variants in patients reviewed here demonstrated deteriorated function of KCC2. These findings are comparable with those observed in rodent models. In particular, possible interference with post-translational mechanisms, e.g., oligomerization, phosphorylation and glycosylation, resulting in deterioration of KCC2 function, may be involved. Further investigations into these mechanisms of KCC2 functional regulation are needed because they are important topics.
Future detailed studies to better understand KCC2 functional domains and mechanistic features of this protein, as well as possible epigenetic regulation, may reveal novel insights into pathogenesis and potential modulation of its activity, providing novel therapeutic routes for neurological and neurodevelopmental diseases. Continued investigation of the pathogenic potential of KCC2 dysfunction may also lead to opportunities for drug development in future.
Acknowledgments:
We thank Dr. H. Saitsu for comments on the manuscript. We thank Ann Turnley, PhD, from
Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.
Funding:
This work was supported by Grants-in-Aid Guilmatre, A., Dubourg, C., Mosca, A.L., Legallic, S., Goldenberg, A., Drouin-Garraud, V., Layet, V., Rosier, A., Briault, S., Bonnet-Brilhault, F., Laumonnier, F., Odent, S., Le Vacon, G., Joly-Helas, G., David, V., Bendavid, C., Pinoit, J.M., Henry, C., Impallomeni, C., Germano, E., Tortorella, G., Di Rosa, G., Barthelemy, C., Andres, C., Faivre, L., 
